Special Issue

Cancer Biology and Precision Oncology

Message from the Guest Editor

Advances in genetic research have revolutionized our understanding of cancer susceptibility, ushering in a transformative era for cancer biology and precision oncology. Comprehensive studies have established significant associations between single-nucleotide polymorphisms (SNPs) and the risk of various cancers, including malignancies of the brain and head and neck, lung, breast, gastrointestinal tract, urological system, gynecological organs, skin, and hematological cancers such as leukemia. These findings underscore the pivotal role of genetic variations in tumorigenesis, highlighting their potential application as molecular markers during cancer risk assessment and as therapeutic targets in precision oncology.

We welcome translational scientists to contribute original research that explores the genetic foundations of all cancer types. Submissions based solely on in silico or dry-lab analyses will not be considered. By publishing groundbreaking discoveries in the Journal of Personalized Medicine (JPM), you can aid in bridging the gap between genetic research and clinical applications. Together, we can advance our understanding of cancers and promote innovations in oncology.

Guest Editor

Dr. Wen-Shin Chang

Terry Fox Cancer Research Laboratory, Department of Medical Research, China Medical University Hospital, Taichung 404327, Taiwan

Deadline for manuscript submissions

20 October 2025



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/228742

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

